To all our CKB CORE users, don’t miss the latest new features now available! Register for a free CORE account here and then login for access. Feel free to contact us at ckbsupport@genomenon.com if you have any questions!

Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06425302
Title A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma (GOLSEEK-2)
Acronym GOLSEEK-2
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Celgene
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | POL | ITA | GBR | FRA | ESP | DEU | CAN | BRA | AUS


No variant requirements are available.